Logo image of KNTE

KINNATE BIOPHARMA INC (KNTE) Stock Fundamental Analysis

NASDAQ:KNTE - Nasdaq - US49705R1059 - Common Stock - Currency: USD

2.65  -0.01 (-0.38%)

After market: 2.65 0 (0%)

Fundamental Rating

2

Overall KNTE gets a fundamental rating of 2 out of 10. We evaluated KNTE against 559 industry peers in the Biotechnology industry. While KNTE has a great health rating, there are worries on its profitability. KNTE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KNTE had negative earnings in the past year.
KNTE had a negative operating cash flow in the past year.
KNTE had negative earnings in each of the past 5 years.
In the past 5 years KNTE always reported negative operating cash flow.
KNTE Yearly Net Income VS EBIT VS OCF VS FCFKNTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

KNTE has a Return On Assets of -64.89%. This is in the lower half of the industry: KNTE underperforms 62.35% of its industry peers.
KNTE has a Return On Equity (-70.70%) which is in line with its industry peers.
Industry RankSector Rank
ROA -64.89%
ROE -70.7%
ROIC N/A
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
KNTE Yearly ROA, ROE, ROICKNTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

KNTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNTE Yearly Profit, Operating, Gross MarginsKNTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for KNTE has been increased compared to 1 year ago.
The number of shares outstanding for KNTE has been increased compared to 5 years ago.
There is no outstanding debt for KNTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KNTE Yearly Shares OutstandingKNTE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
KNTE Yearly Total Debt VS Total AssetsKNTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of 1.00, we must say that KNTE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.00, KNTE is in the better half of the industry, outperforming 64.57% of the companies in the same industry.
There is no outstanding debt for KNTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1
ROIC/WACCN/A
WACCN/A
KNTE Yearly LT Debt VS Equity VS FCFKNTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 13.19 indicates that KNTE has no problem at all paying its short term obligations.
KNTE has a Current ratio of 13.19. This is amongst the best in the industry. KNTE outperforms 86.88% of its industry peers.
KNTE has a Quick Ratio of 13.19. This indicates that KNTE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.19, KNTE belongs to the top of the industry, outperforming 87.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.19
Quick Ratio 13.19
KNTE Yearly Current Assets VS Current LiabilitesKNTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

KNTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.68%, which is quite good.
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KNTE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.70% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNTE Yearly Revenue VS EstimatesKNTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2027 2028 2029 2030 50M 100M 150M 200M 250M
KNTE Yearly EPS VS EstimatesKNTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KNTE. In the last year negative earnings were reported.
Also next year KNTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNTE Price Earnings VS Forward Price EarningsKNTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNTE Per share dataKNTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as KNTE's earnings are expected to grow with 13.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.83%
EPS Next 3Y13.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNTE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINNATE BIOPHARMA INC

NASDAQ:KNTE (4/2/2024, 8:25:40 PM)

After market: 2.65 0 (0%)

2.65

-0.01 (-0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)05-09 2024-05-09/amc
Inst Owners0.91%
Inst Owner Change0%
Ins Owners6.99%
Ins Owner Change0%
Market Cap125.00M
Analysts78
Price Target2.41 (-9.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.27%
Min EPS beat(2)5.59%
Max EPS beat(2)16.95%
EPS beat(4)4
Avg EPS beat(4)8.9%
Min EPS beat(4)1.96%
Max EPS beat(4)16.95%
EPS beat(8)7
Avg EPS beat(8)3.8%
EPS beat(12)7
Avg EPS beat(12)0.57%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.35%
PT rev (3m)-12.47%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)5.3%
EPS NY rev (1m)0%
EPS NY rev (3m)9.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-2.42
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.12
OCFYN/A
SpS0
BVpS3.38
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.89%
ROE -70.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.69%
ROA(5y)-30.56%
ROE(3y)-50.27%
ROE(5y)-34.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.19
Quick Ratio 13.19
Altman-Z 1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)365%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y47.95%
EPS Next 2Y28.83%
EPS Next 3Y13.35%
EPS Next 5Y13.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.09%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.37%
OCF growth 3YN/A
OCF growth 5YN/A